Hydrocortisone plus fludrocortisone for community acquired pneumonia-related septic shock: a subgroup analysis of the APROCCHSS phase 3 randomised trial
Nicholas Heming,Alain Renault,Emmanuelle Kuperminc,Christian Brun-Buisson,Bruno Megarbane,Jean-Pierre Quenot,Shidasp Siami,Alain Cariou,Xavier Forceville,Carole Schwebel,Marc Leone,Jean-Francois Timsit,Benoît Misset,Mohamed Ali Benali,Gwenhael Colin,Bertrand Souweine,Karim Asehnoune,Emmanuelle Mercier,Loïc Chimot,Claire Charpentier,Bruno François,Thierry Boulain,Frank Petitpas,Jean Michel Constantin,Gilles Dhonneur,François Baudin,Alain Combes,Julien Bohé,Jean-François Loriferne,Fabrice Cook,Michel Slama,Olivier Leroy,Gilles Capellier,Auguste Dargent,Tarik Hissem,Rania Bounab,Virginie Maxime,Pierre Moine,Eric Bellissant,Djillali Annane,ANNANE Djillali,BRUN-BUISSON Christian,MISSET Benoit,CHASTRE Jean,BRIVET François,BOHE Julien,SCHWEBEL Carole,SIAMI Shidasp,SLAMA Michel,LEROY Olivier,CAPELLIER Gilles,WOLFF Michel,ALI BEN ALI Mohamed,ANTONINI François,LORIFERNE Jean-François,PETITPAS Franck,CHARPENTIER Claire,CONSTANTIN Jean-Michel,D'HONNEUR Gilles,SOUWEINE Bertrand,FORCEVILLE Xavier,MEGARBANE Bruno,BAUDIN Francois,COLIN Gwenhaël,ASEHNOUNE Karim,QUENOT Jean-Pierre,FRANCOIS Bruno,BOULAIN Thierry,MERCIER Emmanuelle,REIGNIER Jean,AMATHIEU Roland,COOK Fabrice,CARIOU Alain,CHIMOT Loic,Fadel Fouad,Polito Andrea,Clair Bernard,Maxime Virginie,Luis David,Sharshar Tarek,Orlikowski David,RAZAZI Keyvan,DE PROST Nicolas,CARTEAUX Guillaume,GARROUSTE ORGEAS Maité,Philippart François,Combes Alain,Nieszkowska Ania,Jacobs Frederic,Prat Dominique,Lafforgue Patrick,ARA SOMOHANO Claire,MINET Clémence,LUGOSI Maxime,Maizel Julien,Navellou Jean Christophe,Mourvillier Bruno,Bouadma Lila,Timsit Jean François,Martin Claude Denis,Textoris Julien,Wiramus Sandrine,BRUN Clément,RAGONNET Benoît,Ait-Hssain Ali,Combes Alain,Touati Samia,Kuba Jean,Willems Vincent,Lahillaire Pierre,Lassi Mohammed,ANTONA Marion,MEGHENEM Alia,DEMESMAY Marine,Boulet Eric,LOUTREL Olivier,DUMONT Romain,ROQUILLY Antoine,MAHE Pierre-Joachim,DEMEURE dit LATTE Dominique,CHAMPIN Philippe,ARNOULD Jean François,CINOTTI Raphaël,Le FLOCH Ronan,Clavel Marc,Vignon Philippe,Pichon Nicolas,BEGOT Emmanuelle,FEDOU Anne-Laure,CHAPELLAS Catherine,GALY Antoine,Benzekri Lefevre Dalila,Mathonnet Armelle,Bretagnol Anne,Runge Isabelle,BARBIER François,MULLER Grégoire,GAROT Denis,DEQUIN Pierre François,PERROTIN Dominique,LEGRAS Annick,MANKIKIAN Julie,TALEC Patrice,EHRMANN Stephan,JORET Aurélie,LHOMMET Claire,JORET Aurélie,Mancia Claire,ROUVE Emmanuelle,BODET-CONTENTIN Laetitia,JOUAN Youenn,SALMONGANDONNIERE Charlotte,COLIN Gwenhaël,MARTIN-LEFEVRE Laurent,HENRY-LAGARRIGUE Matthieu,YEHIA Aihem,LASCARROU Jean-Baptiste,LEBERT Christine,LACHERADE Jean-Claude,LEVESQUE Eric,NGUYEN Yen-Lan,DAVIAUD Fabrice,BOUGLE Adrien,MIRA Jean Paul,CHICHE Jean Daniel,PENE Frederic,MORICHAU-BEAUCHANT Tristan,GERI Guillaume,DESSALLES Pierre Henri,MONSEAU Yannick,SAINT-LEGER Mélanie,BEDON-CARTE Sandrine,Bodet-Contentin Laetitia,Darwiche Walid,Ehrmann Stephan,Garot Denis,Guillon Antoine,Jouan Youenn,Legras Annick,Mankikian Julie,Mercier Emmanuelle,Morisseau Marlene,Perez Yonatan,Rouve Emmanuelle,Salmon-Gandonniere Charlotte,Helms Julie,Rahmani Hassene,Monnier Alexandra,Merdji Hamid,Clere-Jehl Raphael,Stiel Laure,Studer Antoine,Andreu Pascal,Roudaut Jean-Baptiste,Labruyere Marie,Jacquier Marine,Barbier Francois,Benzekri Dalila,Boulain Thierry,Jacquier Sophie,Mathonnet Armelle,Muller Gregoire,Nai Mai-Anh,Vinatier Isabelle,Tollec Sophie,Roux Damien,Messika Jonathan,Vuillard Constance,Dumont Louis-Marie,Federici Laura,Zucman Noemie,Amouretti Marc,Annane Djillali,Moine Pierre,Meng Paris,Bounab Rania,Fartoukh Muriel-Sarah,Djibre Michel,Elabbadi Alexandre,Azais Marie-Ange,Bachoumas Konstantinos,Bailly Arthur,Bernardon Remi,Blonz Gauthier,Desmedt Luc,Emonet Brian,Fiancette Maud,Henry Matthieu,Lacherade Jean-Claude,Lascarrou Jean-Baptiste,Lebert Christine,Lorber Julien,Lefevre Laurent Martin-,Pouplet Caroline,Vinatier Isabelle,Yehia Aihem,Benghanem Sarah,Charpentier Julien,Vigneron Clara,Chudeau Nicolas,Fedou Anne-Laure,Mancia Claire,Begot Emmanuelle,Daix Thomas,Vignon Philippe,Galy Antoine,Gonzalez Celine,Goudelin Marine,Evrard Bruno,Desachy Arnaud,Vaidie Julien,Gilbert Guillaume,Darreau Cedric,Derrien Benoit,Saint-Martin Marjorie,Tirot Patrice,Landais Mickael,Sedillot Nicolas,Callahan Jean Christophe,Vivier Dominique,Le Moal Charlene,Olivier Pierre-Yves,Marnai Remy,Schneider Francis,Sedillot Nicolas,Tchenio Xavier,Robine Adrien,Poncelin Yves,Bruyere Remi
DOI: https://doi.org/10.1016/s2213-2600(23)00430-7
IF: 102.642
2024-02-01
The Lancet Respiratory Medicine
Abstract:BACKGROUND: Glucocorticoids probably improve outcomes in patients hospitalised for community acquired pneumonia (CAP). In this a priori planned exploratory subgroup analysis of the phase 3 randomised controlled Activated Protein C and Corticosteroids for Human Septic Shock (APROCCHSS) trial, we aimed to investigate responses to hydrocortisone plus fludrocortisone between CAP and non-CAP related septic shock.METHODS: APROCCHSS was a randomised controlled trial that investigated the effects of hydrocortisone plus fludrocortisone, drotrecogin-alfa (activated), or both on mortality in septic shock in a two-by-two factorial design; after drotrecogin-alfa was withdrawn on October 2011, from the market, the trial continued on two parallel groups. It was conducted in 34 centres in France. In this subgroup study, patients with CAP were a preselected subgroup for an exploratory secondary analysis of the APROCCHSS trial of hydrocortisone plus fludrocortisone in septic shock. Adults with septic shock were randomised 1:1 to receive, in a double-blind manner, a 7-day treatment with daily administration of intravenous hydrocortisone 50 mg bolus every 6h and a tablet of 50 μg of fludrocortisone via the nasogastric tube, or their placebos. The primary outcome was 90-day all-cause mortality. Secondary outcomes included all-cause mortality at intensive care unit (ICU) and hospital discharge, 28-day and 180-day mortality, the number of days alive and free of vasopressors, mechanical ventilation, or organ failure, and ICU and hospital free-days to 90-days. Analysis was done in the intention-to-treat population. The trial was registered at ClinicalTrials.gov (NCT00625209).FINDINGS: Of 1241 patients included in the APROCCHSS trial, CAP could not be ruled in or out in 31 patients, 562 had a diagnosis of CAP (279 in the placebo group and 283 in the corticosteroid group), and 648 patients did not have CAP (329 in the placebo group and 319 in the corticosteroid group). In patients with CAP, there were 109 (39%) deaths of 283 patients at day 90 with hydrocortisone plus fludrocortisone and 143 (51%) of 279 patients receiving placebo (odds ratio [OR] 0·60, 95% CI 0·43-0·83). In patients without CAP, there were 148 (46%) deaths of 319 patients at day 90 in the hydrocortisone and fludrocortisone group and 157 (48%) of 329 patients in the placebo group (OR 0·95, 95% CI 0·70-1·29). There was significant heterogeneity in corticosteroid effects on 90-day mortality across subgroups with CAP and without CAP (p=0·046 for both multiplicative and additive interaction tests; moderate credibility). Of 1241 patients included in the APROCCHSS trial, 648 (52%) had ARDS (328 in the placebo group and 320 in the corticosteroid group). There were 155 (48%) deaths of 320 patients at day 90 in the corticosteroid group and 186 (57%) of 328 patients in the placebo group. The OR for death at day 90 was 0·72 (95% CI 0·53-0·98) in patients with ARDS and 0·85 (0·61-1·20) in patients without ARDS (p=0·45 for multiplicative interaction and p=0·42 for additive interaction). The OR for observing at least one serious adverse event (corticosteroid group vs placebo) within 180 days post randomisation was 0·64 (95% CI 0·46-0·89) in the CAP subgroup and 1·02 (0·75-1·39) in the non-CAP subgroup (p=0·044 for multiplicative interaction and p=0·042 for additive interaction).INTERPRETATION: In a pre-specified subgroup analysis of the APROCCHSS trial of patients with CAP and septic shock, hydrocortisone plus fludrocortisone reduced mortality as compared with placebo. Although a large proportion of patients with CAP also met criteria for ARDS, the subgroup analysis was underpowered to fully discriminate between ARDS and CAP modifying effects on mortality reduction with corticosteroids. There was no evidence of a significant treatment effect of corticosteroids in the non-CAP subgroup.FUNDING: Programme Hospitalier de Recherche Clinique of the French Ministry of Health, by Programme d'Investissements d'Avenir, France 2030, and IAHU-ANR-0004.
respiratory system,critical care medicine